 Home > Active Ingredient News > Antitumor Therapy > JCO: Abexiride combined with Fulvestrant has a good effect on patients with PIK3CA mutation HR+/HER2- advanced breast cancer

JCO: Abexiride combined with Fulvestrant has a good effect on patients with PIK3CA mutation HR+/HER2- advanced breast cancer

 Last Update: 2021-04-13
 Source: Internet
 Author: User

Tags

gene therapy blindness

pantoprazol 20 mg

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Recently , JCO published online the patient report outcome of a Phase III SOLAR-1 clinical trial.

Figure 1 Screenshot of the cover of the paper

In the United States, HR+ and HER2- subtype breast cancers account for more than 70% of breast cancer cases .

The PIK3CA mutation cohort of the phase III SOLAR-1 clinical trial enrolled 341 subjects who were randomized 1:1 to receive abexiride 300 mg + fulvestrant 500 mg or placebo + fulvestrant 500 mg on the first course of treatment.

Figure 2 EORTC QLQ-C30 global health status/QoL scale score changes from baseline

However, compared with the placebo group, the social function, diarrhea, loss of appetite, nausea or vomiting, and fatigue in the abecilil group deteriorated.

Figure 3 BPI-SF pain severity index

references:

Ciruelos EM, Rugo HS, Mayer IA, Levy C, Forget F, Delgado Mingorance JI, Safra T, Masuda N, Park YH, Juric D, Conte P, Campone M, Loibl S, Iwata H, Zhou X, Park J, Ridolfi A, Lorenzo I, André F.

org/doi/10.
1200/JCO.
20.
01139?url_ver=Z39.
88-2003&rfr_id=ori:rid:crossref.
org&rfr_dat=cr_pub%20%200pubmed">https://ascopubs.
org/doi/10.
1200/JCO.
20.
01139?url_ver=Z39.
88-2003&rfr_id=ori:rid:crossref.
org&rfr_dat=cr_pub%20%200pubmedorg/doi/10.
1200/JCO.
20.
01139?url_ver=Z39.
88-2003&rfr_id=ori:rid:crossref.
org&rfr_dat=cr_pub%20%200pubmed"> https://ascopubs.
org/doi/10.
1200/JCO .
20.
01139?url_ver=Z39.
88-2003&rfr_id=ori:rid:crossref.
org&rfr_dat=cr_pub%20%200pubmed https://ascopubs.
org/doi/10.
1200/JCO.
20.
01139?url_ver=Z39.
88-2003&rfr_id=ori: rid:crossref.
org&rfr_dat=cr_pub%20%200pubmedleave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Crocetin27876-94-4

CAS No.: 27876-94-4

$1-1.1/G FOB

Betulinic acid472-15-1

CAS No.: 472-15-1

$1-1.1/G FOB

1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane 53-19-0

CAS No.: 53-19-0

Pharmacy Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.